US4050241003
US4050241003
Haemonetics Corporation
Loading chart...
Valuation & History
Quarterly trend of key valuation metrics
| Metric | Current (TTM) TTM Baseline | Q2 '26 30.06.2026 | Q1 '26 31.03.2026 | Q4 '25 31.12.2025 |
|---|---|---|---|---|
Market & Enterprise Value | ||||
Market Cap | 5.4B EUR | 3.41B EUR | 2.55B EUR | 3.75B EUR |
Enterprise Value | 6.39B EUR | 4.36B EUR | 3.53B EUR | 4.61B EUR |
Valuation Multiples | ||||
Trailing P/E | 57.34x | 35.42x | 26.21x | 31.96x |
Forward P/E | 20.4x | -- | -- | -- |
Price to Sales | 3.99x | 2.52x | 1.91x | 3.8x |
Price to Book | 6.45x | 4.07x | 3.2x | 4.12x |
EV/Revenue | 4.72x | 3.23x | 2.65x | 4.67x |
EV/EBITDA | 17.8x | 12.28x | 10x | 16.88x |
Price to FCF (P/FCF) | 17.26x | 11.71x | 9.79x | 18.12x |
EV/FCF | 20.41x | 14.98x | 13.55x | 22.28x |
FCF Yield | 5.79% | 8.54% | 10.21% | 5.52% |